A transition plan developed for the ENGAGE-AF TIMI 48 trial was associated with reduced excess thrombotic and bleeding events in patients moved from one oral anticoagulant to another. In the ...

The anticoagulation management system should be designed to ensure appropriate care transitions for patients receiving anticoagulant therapy. The health care system in the US has a fragmented ...

Anticoagulants Verseon has submitted the Phase I protocol for its lead precision oral anticoagulant (PROAC) candidate, VE-1902, and expects to start first-in-human trials in Q3 2018.